0000950170-24-038731.txt : 20240329
0000950170-24-038731.hdr.sgml : 20240329
20240329165239
ACCESSION NUMBER: 0000950170-24-038731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240327
FILED AS OF DATE: 20240329
DATE AS OF CHANGE: 20240329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bizily Scott
CENTRAL INDEX KEY: 0001920738
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39782
FILM NUMBER: 24804608
MAIL ADDRESS:
STREET 1: C/O 4D MOLECULAR THERAPEUTICS, INC.
STREET 2: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc.
CENTRAL INDEX KEY: 0001650648
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473506994
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5105052680
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc.
DATE OF NAME CHANGE: 20200506
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc
DATE OF NAME CHANGE: 20150811
4
1
ownership.xml
4
X0508
4
2024-03-27
0001650648
4D Molecular Therapeutics, Inc.
FDMT
0001920738
Bizily Scott
C/O 4D MOLECULAR THERAPEUTICS, INC.
5858 HORTON STREET #455
EMERYVILLE
CA
94608
false
true
false
false
Chief Legal Officer
true
Common Stock
2024-03-27
4
M
false
4342
25.98
A
6079
D
Common Stock
2024-03-27
4
M
false
1491
25.98
A
7570
D
Common Stock
2024-03-27
4
S
false
5833
35.0438
D
1737
D
Stock Option (Right To Buy)
25.98
2024-03-27
4
M
false
4342
0
D
2031-09-30
Common Stock
4342
55658
D
Stock Option (Right To Buy)
25.98
2024-03-27
4
M
false
1491
0
D
2031-09-30
Common Stock
1491
54167
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
By: /s/ Scott Bizily
2024-03-29